Significance of transcatheter arterial chemoembolization combined with sorafenib for the treatment of primary hepatocellular carcinoma

VernacularTitle:肝动脉化疗栓塞联合索拉非尼治疗原发性肝癌
Author: Lin ZHENG ; Chenyang GUO ; Hailiang LI ; Hongtao CHENG ; Pu YU
Publication Type:Journal Article
Keywords: Liver neoplasms; Transcatheter arterial chemoembolization; Sorafenib; Interventional radiology
From: Chinese Journal of Digestive Surgery 2013;(3):236-237
CountryChina
Language:Chinese
Abstract: Transcatheter arterial chemoembolization (TACE) was the preferred method of non-operation treatment for hepatocellular carcinoma (HCC).Radical resection of HCC remains difficult,extrahepatic metastasis was not easy to deal with,and repeated treatment aggravated the liver injury,so the long-term efficacy was poor.Sorafenib could control tumor angiogenesis and block the proliferation of tumor cells.A male patient with primary HCC and in the stage Ⅱb according to the Chinese clinical liver cancer staging system was treated by TACE combined with sorafenib and antiviral treatment in Henan Cancer Hospital.After the treatment,the intrahepatic lesions were inactive,and the pulmonary metastasis was partially relieved.The patient was followed up till May 2012,and the survival time was 39 months.The hepatic function was normal,and the hepatitis B virus (HBV) replication was negative.No intervention treatmentrelated complications were detected,and the KPS score was 100.